Antibody-Drug Conjugate– tag –
-
Akari Therapeutics and Whitehawk Therapeutics Partner on Trop2-Targeting ADC AKTX-101, Leveraging Novel PH1 Payload for Immune Activation
Markets Insider USA Overview Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to advance its next-generation Antibody-Drug Conjugate (ADC) lead candidate, AKTX-101. AKTX-101 targets the Trop2 ... -
Optometrists Crucial for Ophthalmic Management of ADC Patients, Understanding Individualized Monitoring Requirements
Optometry Times USA Overview An Optometry Times article underscores the critical role of optometrists in the ophthalmic management of cancer patients undergoing Antibody-Drug Conjugate (ADC) therapy. Given that each ADC agent has unique ... -
Advances in Antibody-Drug Conjugate (ADC) Combination Therapy for Non-Small Cell Lung Cancer: Multi-Target Approaches with Trop-2, HER2, and More
PubMed USA Overview A PubMed review reports significant advances in Antibody-Drug Conjugate (ADC)-based combination therapy strategies for Non-Small Cell Lung Cancer (NSCLC). Focusing on diverse molecular targets such as Trop-2, HER2, HE... -
Model-Optimized Bispecific Antibodies: A Novel Strategy to Enhance ADC Tumor Selectivity
Academia.edu USA Overview Research from Academia.edu elucidates the potential of computationally optimized bispecific antibodies (BsAbs) to enhance the tumor selectivity of Antibody-Drug Conjugates (ADCs). As ADC efficacy remains constra... -
Antibody-Drug Conjugates Evolve from ‘Magic Bullet’ to Standard of Care in Solid Tumors, T-DXd and Combination Therapies Set New Benchmarks
Binaytara USA Overview Antibody-Drug Conjugates (ADCs) have significantly evolved in solid tumor treatment, transitioning from a 'magic bullet' concept to a 'standard of care.' Globally, over 12 ADCs are approved, with more than 300 in c... -
Novartis Reverses ADC Holdout with $1.5B Myricx Deal Amid Sustained M&A Boom in ADC Market
Fierce Biotech USA Overview Novartis, previously hesitant about Antibody-Drug Conjugates (ADCs), has committed up to $1.5 billion to Myricx Bio, signaling a strategic shift into the burgeoning ADC market. This move follows a series of hi... -
Antibody-Drug Conjugates Evolve into Smart Chemotherapy, Datroway Gains FDA Approval for Metastatic Triple-Negative Breast Cancer
Karchem Consulting USA Overview Antibody-Drug Conjugates (ADCs) are evolving into next-generation 'smart chemotherapies' by integrating precise targeting with innovative linker-payload technologies. Novel drug classes like nucleic acid a... -
Antibody-Drug Conjugates (ADCs) Evolve to Standard of Care in Solid Tumor Treatment: 12 Approved, 300 in Development, Focusing on Patient Wellness and Dual-Payload Strategies
Cancer News - Binaytara USA Overview Antibody-drug conjugates (ADCs) have dramatically evolved from 'magic bullets' to a standard of care in cancer treatment, with 12 ADCs approved globally and over 300 in clinical development. This evol... -
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
SGN-CEACAM5C (PF-08046050) Antibody-Drug Conjugate Evaluated in Phase 1 Clinical Trial for Advanced Solid Tumors Including Colorectal Cancer
Fight Colorectal Cancer USA Overview The July 2026 clinical trials roundup highlighted the evaluation of SGN-CEACAM5C (PF-08046050), an antibody-drug conjugate (ADC), in a Phase 1 study for adult patients with advanced solid tumors, incl...
